Technical Analysis for TERN - Terns Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.89 | -1.67% | -0.10 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | -1.67% | |
| 50 DMA Support | Bullish | -1.67% | |
| Outside Day | Range Expansion | -1.67% | |
| Wide Bands | Range Expansion | -1.67% | |
| Gapped Up | Strength | -1.67% | |
| Overbought Stochastic | Strength | -1.67% | |
| Crossed Above 50 DMA | Bullish | -1.67% | |
| NR7 | Range Contraction | -1.67% | |
| Stochastic Reached Overbought | Strength | -1.67% | |
| Earnings Movers | Other | -1.67% |
| Alert | Time |
|---|---|
| 50 DMA Support | 24 minutes ago |
| 60 Minute Opening Range Breakdown | 24 minutes ago |
| Down 2 % | 24 minutes ago |
| Down 1% | about 2 hours ago |
| Up 1% | about 2 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Terns Pharmaceuticals, Inc. Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Bile Acid Chronic Liver Diseases Glucagon Anti Diabetic Drugs
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.03 |
| 52 Week Low | 3.26 |
| Average Volume | 957,775 |
| 200-Day Moving Average | 5.76 |
| 50-Day Moving Average | 5.88 |
| 20-Day Moving Average | 5.29 |
| 10-Day Moving Average | 5.76 |
| Average True Range | 0.43 |
| RSI (14) | 58.33 |
| ADX | 18.42 |
| +DI | 21.91 |
| -DI | 15.93 |
| Chandelier Exit (Long, 3 ATRs) | 4.91 |
| Chandelier Exit (Short, 3 ATRs) | 5.60 |
| Upper Bollinger Bands | 6.33 |
| Lower Bollinger Band | 4.25 |
| Percent B (%b) | 0.84 |
| BandWidth | 39.32 |
| MACD Line | 0.10 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.1372 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.74 | ||||
| Resistance 3 (R3) | 6.72 | 6.46 | 6.62 | ||
| Resistance 2 (R2) | 6.46 | 6.27 | 6.47 | 6.57 | |
| Resistance 1 (R1) | 6.22 | 6.15 | 6.09 | 6.24 | 6.53 |
| Pivot Point | 5.96 | 5.96 | 5.89 | 5.97 | 5.96 |
| Support 1 (S1) | 5.72 | 5.77 | 5.59 | 5.74 | 5.45 |
| Support 2 (S2) | 5.46 | 5.65 | 5.47 | 5.41 | |
| Support 3 (S3) | 5.22 | 5.46 | 5.37 | ||
| Support 4 (S4) | 5.24 |
